References
- Canadian Cancer Society/National Cancer Institute of Canada. Canadian Cancer Statistics 2007. Toronto: Canadian Cancer Society/National Cancer Institute of Canada, 2007.
- Terry J, Torlakovic E, Garratt J, et al Implementation of a Canadian external quality assurance program for breast cancer biomarkers. Appl Immunohistochem Mol Morphol 2009; 17: 375–82.
- Rhodes A, Jasani B, Balaton AJ, Miller KD. Immunohistochemical demonstration of oestrogen and progesterone receptors: correlation of standards achieved on in house tumours with that achieved on external quality assessment material in over 150 laboratories from 26 countries. J Clin Pathol 2000; 53: 292–301.
- Regitnig P, Reiner A, Dinges HP, et al Quality assurance for detection of estrogen and progesterone receptors by immunohistochemistry in Austrian pathology laboratories. Virchows Arch 2002; 441: 328–34.
- Rhodes A, Jasani B, Barnes DM, Bobrow LG, Miller KD. Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systems. J Clin Pathol 2000; 53: 125–30.
- Francis GD, Dimech M, Giles L, Hopkins A. Frequency and reliability of oestrogen receptor, progesteron receptor, and HER2 in breast carcinoma determined by immunohistochemistry in Australasia: results of the RCPA Quality Assurance Program. J Clin Pathol 2007; 60: 1277–83.
- Torlakovic EE, Riddell R, Hewlett B, et al Best practice recommendations for standardization of immunohistochemistry tests. Can J Pathol 2009; 1: 14–25.
- Gown AM. Current Issues in ER and HER2 testing by IHC in breast cancer. Mod Pathol 2008; 21: S8–15.
- Oyama T, Ishikawa Y, Hayashi M, Arihiro K, Horiguchi J. The effects of fixation, processing, and evaluation on Immunohistochemical detection of hormone receptors in breast cancer. Breast Cancer 2007; 14: 182–8.
- Gown AM. Tweaking and nudging toward improved IHC quality. Appl Immunohistochem Mol Morphol 2009; 17: 363–5.
- Mohsin SK, Weiss H, Havighurst T, et al Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study. Mod Pathol 2004; 17: 1545–54.
- Vyberg M. NordiQC: Nordic Immunohistochemical Quality Control. Denmark: NordiQC, 2009. http://www.nordiqc.org/Participation.htm , accessed 25 November 2009.
- Royal College of Pathologists of Australasia Quality Assurance Program (RCPA-QAP). RCPA Anatomical Pathology QAP. Sydney: RCPA-QAP, 2009. http://www.rcpaqapa.netcore.com.au/cgi-bin/site/wrapper.pl?c1=Program , accessed 25 November 2009.
- UK NEQAS. UK NEQAS for Immunocytochemistry and in-situ Hybridisation. London: UK NEQAS, 2009. http://www.ukneqasicc.ucl.ac.uk/ , accessed 25 November 2009.
- Murphy, Hilda. College of American Pathologists: Proficiency Testing. Northfield: CAP, 2009. http://www.cap.org/apps/cap.portal?_nfpb= true&_pageLabel=contact_cap_page&client_ccap_1_actionOverride=/ portlets/ClientCTCAP/viewCase&client_ccap_1confirmationNbr=20091125050930 , accessed 30 November 2009.
- Parker RP, Huntsman DG, Lesack DW, et al Assessment of interlaboratory variation in the immunohistochemical determination of estrogen receptor status using a breast cancer tissue microarray. Am J Clin Pathol 2002; 117: 723–8.
- Sauter G, Lee J, Bartlett JM, Slamon DJ, et al Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol 2009; 8: 1323–33.